Lineage Cell Therapeutics has been added as a member of the broad-market Russell 3000® Index, effective July 1st, as part of the 2024 Russell indexes reconstitution. The annual reconstitution captures the 4,000 largest US stocks as of April 30, 2024, ranking them by total market capitalization. For more: https://lnkd.in/e-W2JN-F #ReplaceandRestore #RussellRecon FTSE Russell, An LSEG Business
Lineage Cell Therapeutics
Biotechnology Research
Carlsbad, CA 5,151 followers
A clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.
About us
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com.
- Website
-
http://www.lineagecell.com
External link for Lineage Cell Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Carlsbad, CA
- Type
- Public Company
- Founded
- 1990
Locations
-
Primary
Get directions
2173 Salk Avenue
Suite 200
Carlsbad, CA 92008, US
-
Get directions
1010 Atlantic Avenue
Suite 102
Alameda, CA 94501, US
Employees at Lineage Cell Therapeutics
Updates
-
Lineage Cell Therapeutics’ CEO Brian Culley is interviewed by Brian Orelli from BiotechTV on the idea for the SCI Investor Symposium and our approach to spinal cord injury treatments. Watch the interview here: https://bit.ly/3W3xvEV #ReplaceandRestore #SCI #SpinalCordInjury
-
-
And that’s a wrap! Thanks so much to all the attendees, sponsors, and presenters, who made #SCISymposium a great success! Keep an eye out for more information on replays from the Symposium in the coming weeks! Lineage Cell Therapeutics California Institute for Regenerative Medicine (CIRM) Christopher & Dana Reeve Foundation #SCI #SpinalCordInjury
-
An insightful session from Tari Suprapto, Ph.D., of Novo Nordisk, Ilan Zipkin, Ph.D., of Supercede Therapeutics & Breakout Ventures, and moderator Liz Meeks of Leerink Partners on the investors’ perspective on #SCI. Lineage Cell Therapeutics, California Institute for Regenerative Medicine (CIRM), Christopher & Dana Reeve Foundation #SpinalCordInjury #CollaboratetoInnovate
-
-
Exciting updates were presented from Neuralink, Lineage Cell Therapeutics, AbbVie, ONWARD Medical, NervGen Pharma Corp., & Kringle Pharma during the Clinical #SCI session, moderated by Joseph Pantginis, Ph.D. of H.C. Wainwright & Co., LLC. Learn more: https://bit.ly/3mzDtOX California Institute for Regenerative Medicine (CIRM), Christopher & Dana Reeve Foundation #SCI #SpinalCordInjury #CollaboratetoInnovate
-
-
Jerod Nieder, Hanna Nieder, Michaela Devins, and Kyle Devins spoke about their lived experiences with #SpinalCordInjury in an engaging discussion with Joseph Pantginis, Ph.D. of H.C. Wainwright & Co., LLC. Lineage Cell Therapeutics, California Institute for Regenerative Medicine (CIRM) (CIRM), Christopher & Dana Reeve Foundation #SCI #SpinalCordInjury
-
-
Today we kick off Day 2 of #SCISymposium with California Institute for Regenerative Medicine (CIRM)’s Lila Collins, Ph.D., and Lineage Cell Therapeutics’ Brian Culley. Stay tuned for updates throughout the conference! See here for more: https://scisymposium.com/ Christopher & Dana Reeve Foundation #SCI #SpinalCordInjury
-
Thanks for a fantastic Day 1 of the #SCISymposium. We look forward to learning more and continuing the great discussions tomorrow! See the agenda here: https://bit.ly/4clRXqf Lineage Cell Therapeutics, California Institute for Regenerative Medicine (CIRM), Christopher & Dana Reeve Foundation #SCI #SpinalCordInjury
-
Great insights learned from the Preclinical #SpinalCordInjury Session, moderated by Baird’s Jack Allen and Adrien Cohen, SCI Ventures, featuring Inteligex, NeuroHagana, Novoron Bioscience, Sania Therapeutics, ReWire Medical, and Axonis Therapeutics. Lineage Cell Therapeutics, California Institute for Regenerative Medicine (CIRM), Christopher & Dana Reeve Foundation #SCI #SpinalCordInjury #SCISymposium
-
-
Christopher & Dana Reeve Foundation’s Chief Scientific Officer Marco Baptista and Lineage Cell Therapeutics CEO Brian Culley kick off Day 1 of #SCISymposium. Stay tuned for updates throughout the conference! See here for more: https://bit.ly/3mzDtOX California Institute for Regenerative Medicine (CIRM), #SCI #SpinalCordInjury